Autoimmunity Biologic Solutions, Inc. (aka Autoimmunity BioSolutions and as ABS) is currently developing a combined diagnostic and therapeutic for treatment of multiple sclerosis (MS). ABS is also deploying the firm's therapeutic platform for autoimmune diseases and other diseases (e.g. cancers) that can be addressed by modulation of patients' immune system. The Company's platform technology is based on research conducted at the University of Texas Medical Branch (UTMB), Galveston, TX. The company having received funding from UTMB, with the principals are using their NIH SBIR funding to pursue pre-clinical development of its MS program.
